Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials

Open access
Tzellos, T., Kyrgidis, A., Zouboulis, C. C.·2013·Journal of the European Academy of Dermatology and Venereology

Abstract

Objective To detect a detrimental or beneficial effect of anti‐IL‐12/23 biological agents (ustekinumab and briakinumab) for the treatment of chronic plaque psoriasis on major adverse cardiovascular events (MACEs). Design Systematic review and meta‐analysis MEDLINE, EMBASE, the Cochrane Skin Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, SciVerse Scopus and ongoing trial registries were searched from inception until December 2011. Search strategy, eligibility criteria, data and statistical analysis methods were defined prior to the literature search. Randomized, placebo‐controlled, double‐blind, monotherapy studies with safety data for MACEs of IL‐12/23 antibodies in adults were eligible for inclusion. Studies of psoriatic arthritis were excluded. Information from each study was extracted independently by two reviewers, using a standardized data extraction form. The primary outcome measure was the number of MACEs during the placebo‐controlled phase of treatment. Results MACEs include myocardial infarction, cerebrovascular accident or cardiovascular death. No statistical heterogeneity across the studies using the I2 statistic (I2 = 0) was found. We employed Peto one‐step method to determine odds ratios and quantify a possible detrimental or beneficial association of IL‐12/23 antibodies treatment with MACEs. We found a possible higher risk of MACEs in those patients treated with IL‐12/23 antibodies compared with those at placebo (OR = 4.23, 95% CI: 1.07–16.75, P = 0.04). This study is unaffected by non‐reporting of outcomes with no events. Conclusion Compared with placebo, there was a significant difference in the rate of MACEs observed in patients receiving anti‐IL‐12/23 biological agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-3083.2012.04500.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 173

Metadata

Authors
Tzellos, T., Kyrgidis, A., & Zouboulis, C. C.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2012-03-08
Volume
27
Issue
5
Pages
622-627
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W1500119734
Cited by
173
References
3
FWCI
9.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/j.1468-3083.2012.04500.x
The paper
Tzellos, T., Kyrgidis, A., & Zouboulis, C. C. (2013). Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2012.04500.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.